Offices in 30 countries
Alvogen is an international privately-owned specialty pharmaceutical company focused on the development, manufacturing and marketing of generic pharmaceuticals, biosimilar products and OTC‘s (over-the-counter medicines. Alvogen‘s lines of business include: product development, contract manufacturing (CMO), contract research (CRO) and sales of generic medicines (Gx), biosimilars and OTC’s. Alvogen is built on the strong foundation of Norwich Pharmaceuticals (NPI), an U.S. company with a 125-year history and an unsurpassed regulatory track record. The Norwich plant, with an annual capacity of five billion tablets and capsules, is Alvogen’s American manufacturing base. Alvogen also has manufacturing and R&D capabilities in Korea and Romania that serve both Asian and CEE markets. Robert Wessman is the Chairman and CEO of Alvogen and leads its global expansion. Alvogen has offices in over 30 countries with 1800 employees.
With more than 200 pharmaceutical projects in development and registration, over 100 product and market launches are expected each year. The group’s product portfolio consists of a broad range of leading molecules for the treatment of conditions in the fields of oncology, cardiology, respiratory, neurology and gastroenterology. Product formulations manufactured and sold by Alvogen include; solid oral dosage, soft gelatin capsules, modified release tablets, transdermals, creams, ointments and injectables. Alvogen also sells and a growing portfolio of OTC (Over-the-counter) medicines and medical devices. North-America is Alvogen’s largest market with approximately half of the group’s sales. Other key markets include: Hungary, Romania, South- Korea, Bulgaria, Serbia, Russia, Ukraine, China, Thailand and Taiwan.
North America Headquarters
Headquarters are in Pine Brook, New Jersey at Ten Bloomfield Avenue